Benitec Biopharma Inc.

NasdaqCM BNTC

Benitec Biopharma Inc. Goodwill for the quarter ending September 30, 2024

Benitec Biopharma Inc. Goodwill is NA for the quarter ending September 30, 2024. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqCM: BNTC

Benitec Biopharma Inc.

CEO	Dr. Jerel A. Banks M.D., Ph.D.
IPO Date	June 24, 2014
Location	United States
Headquarters	3940 Trust Way
Employees	16
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Key trends

Past 5 years